Analytical Data
-
基因名
stxB
- Application
-
别名
stxB；Syntaxin-binding Protein 4
-
种属
E.coli
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P69179
-
表达区间
21-89aa
-
氨基酸序列
TPDCVTGKVEYTKYNDDDTFTVKVGDKELFTNRWNLQSLLLSAQITGMTVTIKTNACHNGGGFSEVIFR
-
分子量
13.3 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The stxB recombinant protein is derived from the Shiga toxin B (StxB) subunit, which is produced by Shiga toxin-producing Escherichia coli (STEC), a significant pathogenic bacterium associated with severe gastrointestinal diseases. Research on stxB has gained prominence due to its role in the pathogenesis of STEC infections, particularly in the development of hemolytic uremic syndrome (HUS), a life-threatening condition. Understanding the structure and function of StxB is critical, as it facilitates the binding of the toxic A subunit to host cells, thereby enabling toxin entry and subsequent cellular disruption. The recombinant form of StxB is being studied for its potential applications in vaccine development and as a therapeutic agent to mitigate the effects of STEC infections. Additionally, stxB recombinant protein can serve as a useful tool in studying cellular signaling pathways and immune responses, paving the way for novel intervention strategies. The production of stxB in heterologous systems allows for detailed characterization and large-scale availability for research purposes. Consequently, it holds promise not only for advancing our understanding of STEC-induced diseases but also for developing effective preventative measures against this pressing public health issue.
